The simultaneous C-suite sell-off at a biotech with 92% analyst bullishness is a red flag. Monitor for an S-3 shelf filing or other dilutive offering in the next 30 days, the cross-filing actuarial verdicts strongly amplify this cluster's signal. If no offering materializes within 2 weeks, the sales may be tax/planning related, but the coordination warrants caution.
ABEO drugs
ABEO drug pipeline →How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 10 $5.36entry
- T+1 · 5mo ago +3.17%α +1.47% · $5.53
- T+5 · 5mo ago +5.41%α +1.98% · $5.65
- T+20 · 4mo ago +32.84%α +29.21% · $7.12
- T+60 · 2mo ago +10.63%α +4.05% · $5.93
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
A cluster of insider sales at ABEO Therapeutics: CEO, CFO, Chief Commercial Officer, and Chief Legal Officer collectively sold ~$540K in open-market transactions over two days (June 8-9, 2026) at ~$5.30-$5.43/share. While the dollar amount is modest relative to the $307M market cap (~0.18%), the participation of the entire C-suite in a coordinated sell-off is notable. The cluster is amplified by cross-filing context (cluster-insider-trades + cluster-offering-context), suggesting potential upcoming dilutive activity or other material developments.
Key Financial Metrics
Key Facts
- CEO Vishwas Seshadri sold 56,344 shares for ~$302K on June 8-9.
- CFO Joseph Vazzano sold 23,692 shares for ~$127K on June 8-9.
- Chief Commercial Officer Madhav Vasanthavada sold 9,620 shares for ~$52K on June 8-9.
- SVP/Chief Legal Officer Brendan O'Malley sold 11,131 shares for ~$60K on June 8-9.
- Total insider sales of ~$540K represent ~0.18% of ABEO's $307M market cap.
- All four C-suite officers sold on both June 8 and June 9 at similar prices, suggesting coordinated timing.
- Cross-filing context shows cluster-insider-trades + cluster-offering-context as an amplifier, raising the probability of a near-term dilutive offering.
Financial Impact
~$540K in insider sales, ~0.18% of market cap
Risk Factors
- Potential near-term dilutive equity offering signaled by cross-filing amplifier
- C-suite selling at a price near recent highs (~$5.43) may indicate insider view that stock is fairly valued or overvalued
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-ABEO-1781051614054 |
Track record
29 reports on ABEO
4 of 6 bullish or bearish reports moved the stock their way by T+1. Best: +15.24% at T+20 after the Sep 29, 2026 report. 4 of 6 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 4/10 Entry price pending
- Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $2.30 Now $2.60 +13.04% settles Nov 17
- Nov 12, 20264d ago SC 13G/A Neutral 3/10 Entry $2.29 to $2.42 Now $2.60 +13.54% ▲ +5.68% +6.04% vs SPY
- Nov 9, 20267d ago Press Release Neutral 5/10 Entry $2.54 to $2.46 Now $2.60 +2.36% ▼ −3.35% −2.98% vs SPY
- Nov 9, 20267d ago 8-K Bearish 6/10 Entry $2.54 to $2.46 Now $2.60 −2.36% ▲ +3.35% +2.98% vs SPY
- Nov 9, 20267d ago Press Release Mixed 6/10 Entry $2.54 to $2.46 Now $2.60 +2.36% ▼ −3.35% −2.98% vs SPY
- Nov 6, 202610d ago Institutional Cluster Neutral 3/10 Entry $4.17 to $2.54 Now $2.60 −37.65% ▼ −39.09% −41.46% vs SPY
- Oct 23, 202624d ago SC 13D Bullish 6/10 Entry $4.40 to $4.31 Now $2.60 −40.91% ▼ −2.05% −2.76% vs SPY
- Sep 29, 20266w ago Insider Cluster Bearish 4/10 Entry $5.25 to $5.01 Now $2.60 +50.48% ▲ +4.57% +4.75% vs SPY
- Sep 18, 20268w ago Press Release Bullish 6/10 Entry $5.57 to $5.67 Now $2.60 −53.32% ▲ +1.80% +0.24% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers